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Abstract: Patients with inflammatory bowel disease (IBD) often present poor bone health and are 13 
40% more at risk of bone fracture. Studies have implicated autophagy in IBD pathology and drugs 14 
used to treat IBD stimulate autophagy in varying degrees, however, their effect on the skeleton is 15 
currently unknown. Here, we have utilised the dextran sulphate sodium (DSS) model of colitis in 16 
mice to examine the effects of the thiopurine drug azathioprine on the skeleton. 10-week-old male 17 
mice (n=6/group) received 3.0% DSS in their drinking water for 4 days, followed by a 14-day 18 
recovery period. Mice were treated with 10mg/kg/day azathioprine or vehicle control. 19 
Histopathological analysis of the colon from DSS mice revealed significant increases in scores for 20 
inflammation severity, extent and crypt damage (P<0.05). Azathioprine provided partial protection 21 
to the colon, as reflected by a lack of significant difference in crypt damage and tissue regeneration 22 
with DSS treatment. MicroCT of vehicle-treated DSS mice revealed azathioprine treatment had a 23 
significant detrimental effect on the trabecular bone microarchitecture, independent of DSS 24 
treatment. Specifically, significant decreases were observed in BV/TV (P<0.01), and trabecular 25 
number (P<0.05), with a concurrent significant increase in trabecular pattern factor (P<0.01). 26 
Immunohistochemical labelling for LC3 revealed azathioprine to induce autophagy in the bone 27 
marrow. Together these data suggest that azathioprine treatment may have a deleterious effect on 28 
IBD patients who may already be at increased risk of osteoporotic bone fractures and thus will 29 
inform on future treatment strategies for patient stratification. 30 
Keywords: bone, inflammatory bowel disease, autophagy, colitis, osteoporosis, azathioprine 31 
 32 
Introduction 33 
Inflammatory bowel disease (IBD) is the name given to a group of conditions that affect the colon 34 
and the small intestine. The two main forms of IBD are ulcerative colitis and Crohn’s disease. Crohn’s 35 
disease can affect any part of the gastrointestinal tract and can cause transmural inflammation. In 36 
contrast, ulcerative colitis causes mucosal inflammation and is limited to the colon [1]. A recent 37 
review by NHS England revealed that the prevalence of IBD was 400 in every 100,000 people which 38 
results in a total cost of £720 million a year in costs to the NHS [2]. 39 
Osteoporosis has been associated as secondary to a number of gastrointestinal conditions, 40 
including IBD [3, 4]. Osteoporosis is a metabolic disease of the bone characterised by a reduction in 41 
bone mineral density and alterations in bone structure, which increases the likelihood of bone 42 
fracture. Significantly, patients with IBD often present with low bone mineral density (BMD), and are 43 
40% more at risk of bone fracture than a healthy individual [3]. 44 
A number of risk factors exist for osteoporosis in IBD patients including malabsorption, chronic 45 
inflammation, low body mass index, use of glucocorticoids, vitamin D deficiency and surgery [5]. 46 
  
Intestinal absorption of key determinants of bone health – e.g. calcium and vitamin D - is often 47 
compromised in IBD due to the reduction of intestinal mucosa [4]. Indeed, patients with IBD present 48 
with vitamin D [6, 7] and calcium deficiencies [8]. IBD is also characterised by the chronic release of 49 
pro-inflammatory cytokines such as IL-6 and tumour necrosis factor-α (TNF-alpha) - the increased 50 
production of these cytokines can stimulate the RANK/RANKL/OPG axis and thus drive osteoclastic 51 
bone resorption [9–11]. Low body mass index is a well established risk factor for low BMD and 52 
fracture, and studies have shown similar associations in patients with IBD [12]. However, other 53 
mechanisms may exist and the development of targeted therapies for bone loss in IBD requires a 54 
better understanding of the underlying cellular mechanisms.  55 
Drugs used to treat IBD include glucocorticoids, immunosuppressants, aminosalicylates (5-56 
ASAs) and biologic agents. Risk of osteoporosis has been shown to be twice as high in IBD patients 57 
on corticosteroids [13], thought to be due to their effects on the RANK/RANKL/OPG axis, sex 58 
hormones and calcium absorption [14]. Conversely, IBD patients on the monoclonal antibody 59 
infliximab have shown increases in their BMD and markers of bone turnover [15–17]. Similarly, 60 
patients on dual anti-TNF-α (infliximab or adalimumab) and azathioprine saw a significant positive 61 
effect on BMD at the lumbar spine [18]. There is an increasing demand to optimise existing medical 62 
therapies through patient stratification and personalised medicine [19]. We, and others, have 63 
previously shown that drugs currently used for treating IBD can affect the autophagy pathway [20]. 64 
Autophagy is an essential self-eating process that can degrade intracellular components such as 65 
organelles, foreign bodies and insoluble protein aggregates through the formation and maturation of 66 
double membrane vesicles, known as autophagosomes [21]. Specifically, we have shown that the 67 
thiopurine drug azathioprine is a potent inducer of autophagy in the colon, however its effects on 68 
bone health have yet to be established [22]. 69 
To directly examine this we have studied bones from a mouse model of IBD using dextran 70 
sulphate sodium (DSS)-induced colitis, which has been extensively used and validated by others to 71 
induce acute and chronic forms of inflammatory bowel disease. This model of colitis in mice is 72 
thought to involve the deterioration of the intestinal epithelial barrier through increased cell 73 
apoptosis, therefore allowing the influx of antigens and micro-organisms and the subsequent 74 
increased expression of inflammatory markers [23, 24]. Histologically, the colitis induced in this 75 
murine model exhibits a wide range of features similar to that seen in man [23]. Further, we and 76 
others have previously shown that DSS treatment causes detrimental effects on bone trabecular 77 
microarchitecture [25, 26]. Here we have used the DSS model to examine the effects of azathioprine 78 
treatment on the skeleton in the context of IBD. The dose and duration of the DSS treatment, and the 79 
age, sex and strain of the mice used were based on our previous study [26]. Male mice were also used 80 
to avoid any confounding actions of oestrogen on the skeleton. Data from this approach will help 81 
inform on personalised therapies for patients with poor bone health in IBD.  82 
Results 83 
Effect of azathioprine on body weight in DSS treated mice 84 
To assess the effects of azathioprine on body weight of mice, colitis was induced with 3% DSS 85 
for 4 days in the presence of azathioprine (DSS/azathioprine) or vehicle control (DSS/vehicle). During 86 
the DSS treatment period (0-4 days), no significant weight loss was observed in any mouse treatment 87 
groups (Fig. 1). Independent of azathioprine treatment, mice exhibited a rapid and significant weight 88 
loss from day 4 following DSS treatment (up to 7% in comparison to non-DSS treated mice, P<0.05). 89 
Following this period of rapid weight loss, DSS/vehicle treated mice proceeded to gain weight until 90 
the end of the study.  Weight gain was observed throughout the study period in the non-DSS/vehicle 91 
treated mice (Fig. 1). In contrast, DSS/azathioprine treated mice exhibited a rapid and significant 92 
weight loss, followed by a brief period of weight gain, which plateaued from day 10 onwards (Fig. 93 
1). Non-DSS/azathioprine treated mice showed no significant weight gain throughout the experiment 94 
(Fig. 1). Full details of the weight measurements and statistical significance over the 18-day treatment 95 
period is detailed in Suppl. Table 1. 96 
  
 97 
Figure 1. Body weight changes of azathioprine and vehicle treated mice treated with DSS followed 98 
by a recovery period. Percentage change in body weight of azathioprine and vehicle mice treated with 99 
or without 3% DSS for 4 days. Data are presented as mean ± S.E.M (n=6/group). 100 
Effect of azathioprine on colon pathology in DSS treated mice 101 
To assess the effects of DSS on mucosal integrity, detailed histological analysis was performed 102 
on the colon from control and DSS/azathioprine or DSS/vehicle mice. Histological scores for all 103 
parameters were minimal in the non-DSS treated mice, and there were no notable differences 104 
observed with azathioprine treatment in this group (Fig. 2). In contrast, histological analysis of the 105 
colon from DSS mice revealed significant increases in scores for inflammation severity (Fig. 2A, 106 
P<0.05) and extent (Fig. 2B, P<0.01), consistent with previous studies and indicative of successful 107 
induction of colitis. It was also observed that the colons from DSS/vehicle mice showed decreased 108 
tissue regeneration (as indicated by the higher regeneration score; Suppl. Table 2 & Fig. 2C, P<0.05) 109 
and increased crypt damage (Fig. 2D, P<0.05) in comparison to the non-DSS/vehicle mice. 110 
No significant differences were observed in tissue regeneration (Fig. 2C) and crypt damage (Fig. 111 
2D) in non-DSS/azathioprine and DSS/azathioprine treated mice, indicative of a partial protection of 112 
azathioprine treatment to the colon. Regional specific changes in the parameters examined were also 113 
observed, with significant pathology localised to the distal aspect of the colon (Suppl. Fig. 1).   114 
  
 115 
Figure 2. Colon pathology of azathioprine and vehicle treated mice treated with 3% DSS. Histological 116 
scoring of colons (A) Inflammation severity score (B) Inflammation extent score (C) Regeneration 117 
score (D) Crypt damage score (E) Representative H&E-stained sections of colon. Data are presented 118 
as mean ± S.D. (n=6/group). P<0.05*, P<0.01**. Scale bar = 100µm. 119 
Effect of azathioprine on bone phenotype in DSS treated mice 120 
DSS-treated mice showed worsened trabecular microarchitecture compared to non-DSS treated 121 
mice as demonstrated by micro computed-tomography (CT) (Fig. 3A). Specifically, DSS-treated mice 122 
exhibited a significant decrease in trabecular thickness (Fig. 3D, P<0.05). Non-significant decreases in 123 
BV/TV (Fig. 3B), and trabecular number (Fig. 3C), and increases in trabecular separation (Fig. 3E) and 124 
pattern factor (Fig. 3F) were also observed in DSS-treated mice. Treatment with azathioprine alone 125 
had a significant detrimental effect on the trabecular bone microarchitecture, independent of DSS 126 
treatment. Indeed, significant decreases were observed in BV/TV (Fig. 3B, P<0.01), and trabecular 127 
number (Fig. 3C, P<0.01), with a concurrent significant increase in trabecular pattern factor (Fig. 3F, 128 
P<0.05) indicative of a more disorganised trabecular structure. No effects of DSS or azathioprine 129 
treatment were observed on trabecular BMD (Fig. 3G).  130 
  
 131 
Figure 3. Trabecular bone microarchitecture of azathioprine and vehicle treated mice treated with 3% 132 
DSS. (A) Representative 3D microCT reconstructions. Trabecular bone parameters between treated 133 
and control groups (B) bone volume/tissue volume (BV/TV), (C) trabecular number (Tb. N.), (D) 134 
trabecular thickness (Tb. Th.), (E) trabecular separation (Tb. Sp.) (F) trabecular pattern factor (Tb. Pf.), 135 
(G) trabecular bone mineral density (BMD). Data are presented as mean ± S.D. (n=6/group). P<0.05*. 136 
P<0.01**. 137 
Induction of autophagy by azathioprine in DSS treated mice 138 
Histological analysis of the tibia sections appeared to confirm the results from the microCT 139 
analysis, with an apparent reduction in bone volume (indicated by increased red osteoid staining) in 140 
the trabecular bone in both the DSS treated mice (Fig. 4A ii, in comparison to Fig. 4Ai) and those 141 
treated with azathioprine (Fig. 4A iii & iv, in comparison to Fig. 4Ai). To examine whether 142 
azathioprine affects autophagy activity in the skeleton of mice, immunohistochemistry for the 143 
autophagy marker LC3 was conducted. LC3 labelling was observed in the osteoblasts lining the 144 
trabecular bone, in the osteocytes and throughout the bone marrow. No differences were observed 145 
between non-DSS and DSS treated mice (Fig. 4Ci, in comparison to Fig. 4Cii). However, azathioprine 146 
treatment appeared to modestly increase the intensity of LC3 labelling, independent of DSS treatment 147 
and in particular within the bone marrow, although no significant differences were observed upon 148 
quantification of immunolabelling intensity (Fig. 4C iii & iv, in comparison to Fig. 4C i and ii, Suppl. 149 
Fig. 2).  150 
  
 151 
Figure 4. Histological staining and immmunohistochemical labelling of tibia trabecular bone in 152 
sections of the tibia. (A) Goldner’s Trichrome (B) H&E (C) LC3 immunolabelling. LC3-positive 153 
immunolabelling is presented as brown staining. Scale bar = 50µm. Images are representative of 4 154 
different mice/group. 155 
Discussion 156 
Patients with IBD often present poor bone health and are 40% more at risk of bone fracture [3]. 157 
Azathioprine is widely used in the treatment of IBD and has been proven to be highly effective, 158 
however it has previously been linked to an increase in fracture risk in humans [27]. Here we utilised 159 
the DSS model of colitis in mice to delineate the effects of the azathioprine on the skeleton. 160 
Histopathological analysis of the colon revealed successful induction of colitis in DSS treated mice, 161 
however, it also revealed no differences in the severity or extent of inflammation in azathioprine 162 
treated mice compared to vehicle-treated mice. This suggests that any noted effects of azathioprine 163 
on the skeleton may be direct and not a consequence of altered nutrition through malabsorption of 164 
nutrients.  165 
There are a number of risk factors associated with IBD-related bone loss including poor nutrient 166 
intake/ absorption, chronic inflammation, and use of glucocorticoids [5]. Central to the inflammatory 167 
response is the chronic release of the pro-inflammatory cytokines IL-6 and TNF-α. Indeed IL-6 has 168 
been identified as the predominant cytokine mediating the bone abnormalities, and genetic variations 169 
in IL-6 correlate well with the clinical course of IBD and the extent of bone loss [28, 29]. These pro-170 
inflammatory cytokines are known to promote bone loss directly, but also through altered sensitivity 171 
and secretion of growth hormone and insulin-like growth factor in IBD [30–32]. DSS-induced colitis 172 
is the result of deterioration of the epithelial barrier, allowing for the influx of antigens and 173 
microorganisms, and prompting the increased expression of these pro-inflammatory mediators [23, 174 
24]. Indeed this has previously been shown to have detrimental effects on bone quality [25, 26]. In 175 
accordance with these studies, we observed worsened bone trabecular microarchitecture with DSS 176 
treatment in our mice. Further, when azathioprine was administered alone it was also found to have 177 
a detrimental effect on bone microarchitecture. This is consistent with previous reports of increased 178 
overall skeletal fracture risk in individuals prescribed azathioprine [27], although contradicts that in 179 
which combination of anti-TNF-α and azathioprine had a positive effect [18]. The anti-TNF-α 180 
monoclonal antibody infliximab has on its own been associated with increases in BMD and markers 181 
of bone which may provide explanation as to the disparity between these results [15–17]. In addition, 182 
it has been suggested that azathioprine can disrupt the bone remodelling process in a rat model by 183 
  
suppressing T lymphocytes causing disturbances in the RANKL system responsible for osteoclast 184 
formation and activity [33]. Specifically, the authors found that although the length and diameter of 185 
the bones remained unchanged, azathioprine caused an overall reduction in femur and tibia mass, 186 
whilst also reducing the calcium content. Further, the thickness of the trabeculae in the femur was 187 
found to be reduced in rats when treated with azathioprine in both the distal epiphysis and 188 
metaphysis [33]. The bisphosphonate alendronate prevented the development of these skeletal 189 
changes when administered in combination with azathioprine [33]. These findings complement our 190 
findings here that the administration of azathioprine may contribute to overall bone loss and 191 
trabecular bone deterioration. This suggests that azathioprine alone may therefore not be a suitable 192 
drug of choice for IBD patients who are more at risk of osteoporotic bone fractures, such as the 193 
elderly. 194 
We hypothesised that the detrimental effects on bone caused by azathioprine may result in the 195 
induction of the autophagy pathway, as azathioprine has already been shown to induce this process 196 
in peripheral blood mononuclear cells and colorectal cancer cells [22, 34]. Autophagy is a homeostatic 197 
process in which cells degrade protein aggregates and damaged organelles [35]. Upon the induction 198 
of autophagy, LC3-I becomes lipidated and becomes LC3-II before inserting into the autophagosome 199 
membrane [36]. Because of this, the detection of LC3 within a sample is a recognised marker used to 200 
show the presence of autophagy. Here we revealed increased LC3 labelling in our azathioprine 201 
treated mice, suggestive of autophagy induction. This suggests that azathioprine is an effective 202 
inducer of autophagy activity in the skeleton. The reasons for this are currently speculative, as it is 203 
currently not known whether autophagy is indirectly induced as a survival mechanism to cope with 204 
the adverse effects caused by azathioprine on bone health. Similarly, the precise effects of 205 
azathioprine on osteoblast function are currently unknown. The effects of another autophagy inducer 206 
- rapamycin – are however well documented, albeit somewhat controversial in their findings. It has 207 
been shown that rapamycin, in the presence of lipopolysaccharides, can promote the differentiation 208 
of human embryonic stem cells (hESCs) into mature osteoblasts by modulating mTOR signalling [37, 209 
38]. However, it was also found that rapamycin inhibits osteoblast proliferation and differentiation 210 
in MC3T3-E1 cells. It was observed that even at low concentrations (0.1-20 nM), rapamycin reduced 211 
osteocalcin and osterix mRNA expression in differentiating MC3T3-E1 osteoblasts, as well as 212 
reducing their mineralisation capacity [39]. Therefore, this further highlights the need to understand 213 
more fully the mechanism of action of azathioprine before a better level of care for patients can be 214 
provided. 215 
In conclusion, the data in this manuscript suggest that azathioprine treatment may have a 216 
deleterious effect on bone health in IBD patients who may already be at increased risk of osteoporotic 217 
bone fractures and thus will inform on future treatment strategies for patient stratification. 218 
Materials and Methods 219 
Animals 220 
Male 10-week old C57BL/6J mice (n=6/group) (Charles River, UK) were treated with 3% DSS 221 
(molecular mass ~40,000kD; MP Biomedical, UK) in their drinking water ad libitum for 4 days, 222 
following which they were given normal tap water for a 14-day recovery period. Control (non-DSS 223 
treated) male mice received normal tap water for the duration of the study. The dose and duration of 224 
the DSS treatment was based on previous studies using the same mouse strain, age and sex [26]. It is 225 
important to note that this model is unable to distinguish between ulcerative colitis and Crohn’s 226 
disease. Mice were treated using an oral gavage daily throughout the experiment with 10mg/kg/day 227 
of azathioprine or a vehicle control (n=6/group). The health status of the DSS-treated mice was scored 228 
daily, with particular attention paid to their coat condition, mobility, presence of blood in stools and 229 
eye clarity. Body weights of all mice were recorded daily. After the 14-day recovery period, the mice 230 
were culled and blood, colon and bone samples collected. Mice were kept in polypropylene cages, 231 
with light/dark 12-hr cycles, at 21 ± 2°C, and fed ad libitum with maintenance diet (Special Diet 232 
Services, Witham, UK). All experimental protocols were approved by Roslin Institute’s Animal Users 233 
  
Committee and the animals were maintained in accordance with UK Home Office guidelines for the 234 
care and use of laboratory animals.  235 
Colon pathology 236 
The colon was dissected from all mice, measured and fixed in 4% paraformaldehyde (PFA) for 237 
24 hours. Each colon was divided into 3 transverse segments including proximal, middle and distal 238 
portions. Tissue processing, wax embedding, sectioning (5µm thick) and Hematoxylin and eosin 239 
(H&E) staining were conducted following routine procedures. Colon pathology was graded blind on 240 
sections from all 3 segments of each mouse using an established histological grading scheme (Suppl. 241 
Table 2) [40, 41]. Scores from all three segments were averaged to provide an overall pathology score, 242 
as well as were analysed in the separate regions of the colon.  243 
Bone histology & immunohistochemistry 244 
The tibia was dissected from all mice, fixed in 4% formaldehyde, and decalcified in 10% 245 
ethylenediaminetetraacetic acid (EDTA) at 4oC. Tissue processing, wax embedding, and sectioning 246 
(5µm thick) were done following routine procedures. Tibia sections were stained for histological 247 
analysis using the Goldner’s stain, and H&E following standard protocols. For 248 
immunohistochemistry, sections were dewaxed in xylene, rehydrated in graded alcohol and 249 
incubated for 90 minutes at 70°C in 10 mM citrate buffer for antigen retrieval. Any endogenous 250 
peroxidase activity was blocked by using 0.3% H2O2 for 30 minutes at room temperature. LC3 (1:500, 251 
polyclonal raised in rabbit; MBL) antibodies were used with an appropriate IgG control (Suppl. Fig. 252 
2). The Vectastain ABC universal kit (Vector Laboratories, Peterborough, UK) was used according to 253 
the manufacturer’s instructions. The samples were counterstained with haematoxylin before being 254 
dehydrated and mounted using DePex. Quantification of immunolabelling was conducted using 255 
reciprocal intensity and the open source software Image J (http://fiji.sc/) [42].  256 
microCT 257 
To evaluate trabecular microarchitecture and cortical bone geometry of the tibia from control 258 
and DSS-treated mice, we used microCT (Skyscan 1172 X-ray microtomograph, Bruker, Kontich, 259 
Belgium) as described previously [43]. In brief, high-resolution scans with an isotropic voxel size of 260 
5 µm were acquired (60 kV, 0.5 mm aluminium filter, 0.6° rotation angle). Two images were averaged 261 
at each rotation angle. Scan reconstruction was conducted using NRecon software (Bruker) and each 262 
bone was analysed using CtAN (Bruker). For the trabecular analysis, the base of the growth plate was 263 
used as a standard reference point. A 1.25mm trabecular bone region, located at 5% of the total length 264 
beneath this reference point, was analysed. To investigate the changes in the cortical bone geometry, 265 
two 0.5mm sections were analysed at 37% and 50% of the total bone length from the reference starting 266 
slice (first appearance of the medial tibial condyles). To assess BMD, phantoms were used to calibrate 267 
the CTAn software. BMD phantoms of known calcium hydroxyapatite mineral densities of 0.25 and 268 
0.75 g/cm3 were scanned and reconstructed using the same parameters as used for bone samples.     269 
Statistical analysis 270 
Data are expressed as the mean ± standard deviation (S.D.). A power analysis was conducted on 271 
microCT data from a previous study using an identical model and 6 experimental mice per group 272 
were required to detect statistically significant differences in the bone trabecular microarchitecture 273 
[26]. Analysis was performed by one-way analysis of variance (ANOVA) with appropriate post-hoc 274 
tests. P<0.05 was considered to be significant and noted as *, with P values of <0.01 and <0.001 were 275 
noted as ** and *** respectively.  276 
Supplementary materials:  277 
Suppl. Table 1: Significance of weight changes between treatment groups of mice in DSS-study taken daily over the 18-day 278 
treatment period. 279 
  
Suppl. Table 2: Scoring criteria of colon pathology. 280 
Suppl. Fig. 1: Colon pathology of azathioprine and vehicle treated mice treated with 3% DSS. Histological scoring of 281 
proximal, middle and distal regions of the colon (A) Inflammation severity score (B) Inflammation extent score (C) 282 
Regeneration score (D) Crypt damage score. Data are presented as mean ± S.D. (n=6/group). P<0.05*, P<0.01**, 283 
P<0.001***.  284 
Suppl. Fig. 2: (A) Appropriate IgG control for LC3 immunolabelling. Scale bar = 50µm. Quantification of 285 
immunohistochemistry – reciprocal intensity of (B) osteoblasts (C) bone marrow (D) whole bone slice. Data are presented 286 
as mean ± S.D. 287 
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